Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Attenuated androgens
2 evidence topics · 2 sources
Second-line position, adverse effects, and monitoring
“We suggest IV C1-INH, attenuated androgens (at the lowest effective dose, preferably not exceeding 200 mg per day), or antifibrinolytics as second-line options for LTP in patients for whom first-line therapies are not available, not feasible, or not tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attenuated androgens are strongly associated with virilization in women, dyslipidemia, and hepatotoxicity, with an increased risk of hepatic neoplasms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They cannot be used during pregnancy or in the pediatric and adolescent populations because they interfere with growth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend semi-annual monitoring when using androgens, including a complete blood count, chemistry panel, lipid panel, and routine urinalysis, along with annual liver ultrasound.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote